Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25754610 | 0.92 | HRH3 (0.42) | HRH3CYP1A2MAPK1SMN1; SMN2THRA | |
| SCHEMBL25754615 | 0.92 | HRH3 (0.42) | HRH3CYP1A2MAPK1SMN1; SMN2THRA | |
| SCHEMBL25754594 | 0.90 | CYP1A2 (0.42) | HRH3CYP1A2MAPK1SMN1; SMN2THRA | |
| SCHEMBL25754605 | 0.87 | HRH3 (0.43) | HRH3ALDH1A1MAOB | |
| SCHEMBL25754612 | 0.87 | HRH3 (0.43) | HRH3ALDH1A1MAOB | |
| SCHEMBL25754592 | 0.85 | ALDH1A1 (0.50) | HRH3CYP1A2MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL25754754 | 0.84 | KMT2A (0.36) | HRH3CYP1A2MAPK1SMN1; SMN2THRA | |
| SCHEMBL25754752 | 0.82 | SMN1; SMN2 (0.38) | HRH3CYP1A2MAPK1SMN1; SMN2THRB | |
| SCHEMBL25754758 | 0.82 | HRH3 (0.39) | HRH3CYP1A2MAPK1SMN1; SMN2MAPT | |
| SCHEMBL25754203 | 0.76 | CES2 (0.47) | THRBALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | HRH3 1596/4885CYP1A2 3367/4885MAPK1 3542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.